[1] |
Maubec E. Update of the management of cutaneous squamous⁃cell carcinoma[J]. Acta Derm Venereol, 2020,100(11):adv00143. doi: 10.2340/00015555⁃3498.
|
[2] |
Dańczak⁃Pazdrowska A, Pazdrowski J, Polańska A, et al. Profiling of microRNAs in actinic keratosis and cutaneous squamous cell carcinoma patients[J]. Arch Dermatol Res, 2022,314(3):257⁃266. doi: 10.1007/s00403⁃021⁃02221⁃2.
|
[3] |
Savas S, Skardasi G. The SWI/SNF complex subunit genes: their functions, variations, and links to risk and survival outcomes in human cancers[J]. Crit Rev Oncol Hematol, 2018,123:114⁃131. doi: 10.1016/j.critrevonc.2018.01.009.
|
[4] |
Mancini M, Cappello A, Pecorari R, et al. Involvement of transcribed lncRNA uc.291 and SWI/SNF complex in cutaneous squamous cell carcinoma[J]. Discov Oncol, 2021,12(1):14. doi: 10.1007/s12672⁃021⁃00409⁃6.
|
[5] |
Jones CA, Tansey WP, Weissmiller AM. Emerging themes in mechanisms of tumorigenesis by SWI/SNF subunit mutation[J]. Epigenet Insights, 2022,15:251686572 21115656. doi: 10.1177/251686 57221115656.
|
[6] |
刘念念, 夏晓雪, 施健, 等. 活化转录因子2在皮肤鳞状细胞癌及其相关疾病中的表达[J]. 南通大学学报(医学版), 2023,(1):34⁃37. doi: 10.16424/j.cnki.cn32⁃1807/r.2023.01.008.
|
[7] |
Miyai K, Kawamura K, Ito K, et al. Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma[J]. BMC Cancer, 2022,22(1):787. doi: 10.1186/s12885⁃022⁃09893⁃7.
|
[8] |
Zeng S, Fu L, Zhou P, et al. Identifying risk factors for the prognosis of head and neck cutaneous squamous cell carcinoma: a systematic review and meta⁃analysis[J]. PLoS One, 2020,15(9):e0239586. doi: 10.1371/journal.pone.0239586.
|
[9] |
Dagogo⁃Jack I, Schrock AB, Kem M, et al. Clinicopathologic characteristics of BRG1⁃deficient NSCLC[J]. J Thorac Oncol, 2020,15(5):766⁃776. doi: 10.1016/j.jtho.2020.01.002.
|
[10] |
Lang JD, Hendricks W. Identification of driver mutations in rare cancers: the role of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)[J]. Methods Mol Biol, 2018,1706:367⁃379. doi: 10.1007/978⁃1⁃4939⁃7471⁃9_20.
|
[11] |
Jubierre L, Soriano A, Planells⁃Ferrer L, et al. BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways[J]. Oncogene, 2016,35(39):5179⁃5190. doi: 10.1038/onc.2016.50.
|
[12] |
Giles KA, Gould CM, Achinger⁃Kawecka J, et al. BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer[J]. Clin Epigenetics, 2021,13(1):37. doi: 10.1186/s13148⁃021⁃01023⁃7.
|
[13] |
Mashtalir N, D′Avino AR, Michel BC, et al. Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes[J]. Cell, 2018,175(5):1272⁃1288.e20. doi: 10.1016/j.cell.2018.09.032.
|
[14] |
Shaykevich A, Silverman I, Bandyopadhyaya G, et al. BRG1: promoter or suppressor of cancer? The outcome of BRG1′s interaction with specific cellular pathways[J]. Int J Mol Sci, 2023,24(3):2869. doi: 10.3390/ijms24032869.
|
[15] |
Wang Y, Yang CH, Schultz AP, et al. Brahma⁃related gene⁃1 (BRG1) promotes the malignant phenotype of glioblastoma cells[J]. J Cell Mol Med, 2021,25(6):2956⁃2966. doi: 10.1111/jcmm. 16330.
|
[16] |
Kelso T, Porter DK, Amaral ML, et al. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A⁃mutant cancers[J]. Elife, 2017,6:e30506. doi: 10.7554/eLife. 30506.
|
[17] |
Li ZJ, Zhang JP, Li DY, et al. ATF2 accelerates the invasion and metastasis of hepatocellular carcinoma through targeting the miR⁃548p/TUFT1 axis[J]. Hepatol Res, 2022,52(3):281⁃297. doi: 10.1111/hepr.13740.
|
[18] |
Lau E, Feng Y, Claps G, et al. The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation[J]. Sci Signal, 2015,8(406):ra124. doi: 10.1126/scisignal.aac6479.
|
[19] |
Watson G, Ronai ZA, Lau E. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease[J]. Pharmacol Res, 2017,119:347⁃357. doi: 10.1016/j.phrs.2017.02.004.
|